Boardroom Alpha
8-K primary document
RLYB · Current Report (Form 8-K) · Filed June 1, 2026

Rallybio Corp8-K exhibit

d19106dex108.htm
EX-10.8

Exhibit 10.8

SECOND AMENDMENT TO

EMPLOYMENT AGREEMENT

This second amendment (this “Amendment”) amends the Employment Agreement (the “Agreement”), dated as of February 1, 2023, as amended by that certain Amendment to Employment Agreement (the “First Amendment”), between Rallybio Corporation, a Delaware corporation (the “Company”), and Jonathan I. Lieber (the “Executive”) and is effective as of the date set forth on the signature page hereto. Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Agreement.

WHEREAS, the Company and the Executive entered into the Agreement;

WHEREAS, pursuant to the First Amendment, the definition of “Change in Control” in the Agreement was amended to provide that the transactions contemplated by that certain Agreement and Plan of Merger, dated as of March 1, 2026, by and among the Company, Farmington Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company, and Candid Therapeutics, Inc., a Delaware corporation (the “Prior Merger Agreement”), would constitute a “Change in Control” for purposes of the Agreement;

WHEREAS, the Prior Merger Agreement has been terminated; and

WHEREAS, the Company and the Executive desire to further amend certain provisions of the Agreement to update the definition of “Change in Control.”

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. The definition of “Change in Control” in the Agreement, as amended by the First Amendment, is hereby further amended and restated to include the following clause at the end of such definition:

2. “further, provided, however, that any business combination (including a reverse merger) pursuant to which the stockholders of the Company immediately prior to the transaction beneficially own securities representing less than 50% of the voting power of the Company following the transaction shall constitute a ‘Change in Control.’”

3. The Company and the Executive acknowledge and agree that a “Change in Control” has not occurred under the Agreement as of the date of this Amendment.

4. Except as expressly amended hereby, the Agreement (as amended by the First Amendment) shall remain in full force and effect in accordance with its terms.


5. The Executive acknowledges and agrees that (i) this Amendment may be executed in two or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument, (ii) this Amendment may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, will constitute an original signature for all purposes hereunder, and (iii) such signature by the Company will be binding against the Company and will create a legally binding agreement when this Amendment is countersigned by the Executive.

[Signature page follows.]

 

-2-


The Company, by its duly authorized officer, and the Executive have executed this Amendment.

 

RALLYBIO CORPORATION
By:  

/s/ Stephen Uden

Name:  

Stephen Uden

Title:  

Chief Executive Officer

Agreed and Accepted:

/s/ Jonathan I. Lieber

Jonathan I. Lieber

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer